Personalis stock climbed sharply in morning trading, jumping 12.91% to $6.82 after a key Medicare decision expanded coverage for the company’s NeXT Personal MRD test. The Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program extended reimbursement for the NeXT Personal test to include immunotherapy monitoring for patients with late-stage solid tumors, creating a fresh commercial inflection point for the company.
Analysts and market participants had anticipated that commercial teams would await a CMS decision on immunotherapy monitoring before ramping up sales efforts. Management had previously indicated that 2026 guidance did not assume immunotherapy coverage, so the announcement represented a tangible upside surprise to investors.
Adding to the positive momentum, Deep Track Capital and related entities disclosed beneficial ownership of 5,760,627 shares of Personalis common stock, equal to a 5.51% stake, as of May 12, 2026. Institutional ownership disclosure often signals heightened investor confidence, and this filing arrived alongside the Medicare expansion.
On the analyst front, BTIG kept a Buy rating on Personalis but trimmed its price target to $11 from $13, citing sector-wide multiple compression. The bank’s continued Buy stance, paired with the CMS coverage expansion, helped reinforce the bullish narrative among investors.
The Medicare coverage update also ties directly to Personalis’ recent operational momentum. In the first quarter, the company beat revenue expectations and reported strong demand for its NeXT Personal MRD test, which grew 258% year-over-year and 26% quarter-over-quarter. More than 1,000 oncologists ordered the test in the first quarter, underscoring growing clinical adoption.
Personalis reiterated full-year 2026 revenue guidance of $78 million to $80 million and anticipates significant growth in biopharma MRD revenue, which it expects to more than double year-over-year. The company is tracking to deliver approximately $20 million to $21 million of biopharma revenue this year, and management projects additional growth from MRD biopharma clinical trials in the second half of 2026.
Market breadth provided little help for the stock’s rise, indicating the move was driven by company-specific developments. The S&P 500 was down 0.25%, the Dow Jones Industrial Average slipped 0.41%, and the Nasdaq declined 0.20% during the same session, highlighting that PSNL’s gain was largely independent of broader market direction.
Investors and analysts characterized the convergence of the CMS coverage decision, the institutional ownership disclosure, and a strong first-quarter performance as a meaningful set of catalysts. Because 2026 guidance had been prepared without assuming immunotherapy coverage, the new reimbursement decision represents an incremental revenue opportunity that could accelerate Personalis’ path toward commercial scale and improved margins, assuming the company can convert the opportunity into volume and sustained payment realization.
Looking ahead, Personalis expects MRD-related biopharma clinical trial activity to expand later in 2026, which is consistent with the company’s projection for material biopharma revenue growth this year. The immediate market reaction reflects investor focus on reimbursement clarity, institutional interest, and recent operational beats as primary drivers behind the stock’s rally.
Contextual note: This article presents the company events, financial metrics, analyst actions, institutional ownership disclosure, and market moves as reported. Where the article’s information is limited, those limitations are reflected rather than expanded upon.